Zeroing in on neurodegenerative α -synuclein
Nature Reviews Drug Discovery 16, 371 (2017).
doi:10.1038/nrd.2017.95
Author: Katie Kingwell
In the search for the first disease-modifying therapy for Parkinson disease, drug developers are advancing α-synuclein-targeted agents into proof-of-concept clinical trials.
Source: Nature Reviews Drug Discovery - Category: Drugs & Pharmacology Authors: Katie Kingwell Tags: News and Analysis Source Type: research